Breast Cancer, Clinical Obstetrics and Gynecology, vol.54, issue.1, pp.96-102, 2011. ,
DOI : 10.1097/GRF.0b013e3182080056
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, JNCI Journal of the National Cancer Institute, vol.90, issue.21, pp.1601-1608, 1998. ,
DOI : 10.1093/jnci/90.21.1601
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, The Lancet, vol.365, issue.9472, pp.1687-1717, 2005. ,
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials, Journal of Clinical Oncology, vol.26, issue.1, pp.44-53, 2008. ,
DOI : 10.1200/JCO.2007.11.3787
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-1684, 2005. ,
DOI : 10.1056/NEJMoa052122
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, The Lancet Oncology, vol.12, issue.1, pp.21-29, 2011. ,
DOI : 10.1016/S1470-2045(10)70266-7
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2???Negative Metastatic Breast Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3239-3247, 2010. ,
DOI : 10.1200/JCO.2008.21.6457
URL : https://hal.archives-ouvertes.fr/inserm-00508083
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: The HERNATA Study, Journal of Clinical Oncology, vol.29, issue.3, pp.264-271, 2011. ,
DOI : 10.1200/JCO.2010.30.8213
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study, Journal of Clinical Oncology, vol.27, issue.27, pp.4530-4535, 2009. ,
DOI : 10.1200/JCO.2008.21.1136
p53 and breast cancer, an update, Endocrine Related Cancer, vol.13, issue.2, pp.293-325, 2006. ,
DOI : 10.1677/erc.1.01172
A deadly inheritance, Nature, vol.348, issue.6303, pp.681-682, 1990. ,
DOI : 10.1038/348681a0
Structural aspects of the p53 protein in relation to gene evolution, Oncogene, vol.5, issue.7, pp.945-952, 1990. ,
To die or not to die: how does p53 decide?, Oncogene, vol.23, issue.16, pp.2809-2818, 2004. ,
DOI : 10.1038/sj.onc.1207516
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation, Annals of the New York Academy of Sciences, vol.17, issue.1, pp.121-137, 2000. ,
DOI : 10.1111/j.1749-6632.2000.tb06705.x
The C terminus of p53 binds the N-terminal domain of MDM2, Nature Structural & Molecular Biology, vol.3, issue.8, pp.982-989, 2010. ,
DOI : 10.1101/gad.1795709
C-Terminal Ubiquitination of p53 Contributes to Nuclear Export, Molecular and Cellular Biology, vol.21, issue.24, pp.8521-8532, 2001. ,
DOI : 10.1128/MCB.21.24.8521-8532.2001
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities, Oncogene, vol.21, issue.18, pp.2929-2943, 2005. ,
DOI : 10.1038/sj.onc.1208474
Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli, Cellular Signalling, vol.22, issue.3, pp.564-571, 2010. ,
DOI : 10.1016/j.cellsig.2009.11.014
Genetic Stabilization by p53 Involves Growth Regulatory and Repair Pathways, Journal of Biomedicine and Biotechnology, vol.1, issue.1, pp.7-10, 2001. ,
DOI : 10.1155/S1110724301000043
Histone deacetylase inhibitors: Signalling towards p21cip1/waf1, The International Journal of Biochemistry & Cell Biology, vol.39, issue.7-8, pp.1367-1374, 2007. ,
DOI : 10.1016/j.biocel.2007.03.001
p53 modulation of the DNA damage response, Journal of Cellular Biochemistry, vol.25, issue.4, pp.883-896, 2007. ,
DOI : 10.1002/jcb.21091
The signals and pathways activating cellular senescence, The International Journal of Biochemistry & Cell Biology, vol.37, issue.5, pp.961-976, 2005. ,
DOI : 10.1016/j.biocel.2004.10.013
The evolution of diverse biological responses to DNA damage: insights from yeast and p53, Nature Cell Biology, vol.3, issue.12, pp.277-286, 2001. ,
DOI : 10.1038/ncb1201-e277
p53 and autophagy in cancer: Guardian of the genome meets guardian of the proteome, European Journal of Cancer, vol.47, issue.1, pp.44-50, 2011. ,
DOI : 10.1016/j.ejca.2010.10.020
p53 Has a Direct Apoptogenic Role at the Mitochondria, Molecular Cell, vol.11, issue.3, pp.577-590, 2003. ,
DOI : 10.1016/S1097-2765(03)00050-9
Two faces of p53: aging and tumor suppression, Nucleic Acids Research, vol.35, issue.22, pp.7475-7484, 2007. ,
DOI : 10.1093/nar/gkm744
Autophagy regulation by p53, Current Opinion in Cell Biology, vol.22, issue.2, pp.181-185, 2010. ,
DOI : 10.1016/j.ceb.2009.12.001
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling, Cell, vol.134, issue.3, pp.451-460, 2008. ,
DOI : 10.1016/j.cell.2008.06.028
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis, Cell, vol.126, issue.1, pp.121-134, 2006. ,
DOI : 10.1016/j.cell.2006.05.034
Regulation of autophagy by cytoplasmic p53, Nature Cell Biology, vol.13, issue.6, pp.676-687, 2008. ,
DOI : 10.1093/emboj/19.21.5720
Mutant p53 protein localized in the cytoplasm inhibits autophagy, Cell Cycle, vol.7, issue.19, pp.3056-3061, 2008. ,
DOI : 10.4161/cc.7.19.6751
Death through a tragedy: mitotic catastrophe, Cell Death and Differentiation, vol.5, issue.7, pp.1153-1162, 2008. ,
DOI : 10.1002/(SICI)1097-0185(199605)245:1<1::AID-AR1>3.0.CO;2-2
Cell death by mitotic catastrophe: a molecular definition, Oncogene, vol.23, issue.16, pp.2825-2837, 2004. ,
DOI : 10.1038/sj.onc.1207528
The p53 pathway: positive and negative feedback loops, Oncogene, vol.12, issue.17, pp.2899-2908, 2005. ,
DOI : 10.1038/sj.onc.1208615
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome, p53, vessel count, and vascular endothelial growth factor expression in human colon cancer, pp.1175-1186, 1998. ,
DOI : 10.1007/s00109-007-0221-2
Neoangiogenesis in colon cancer: Correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression, Oncology Reports, vol.9, issue.3, pp.617-620, 2002. ,
DOI : 10.3892/or.9.3.617
Activation of the HIF pathway in cancer, Current Opinion in Genetics & Development, vol.11, issue.3, pp.293-299, 2001. ,
DOI : 10.1016/S0959-437X(00)00193-3
Arrest, Radiation Research, vol.168, issue.6, pp.706-715, 2007. ,
DOI : 10.1667/RR1075.1
URL : https://hal.archives-ouvertes.fr/hal-00719604
Expression of SUMO-2/3 Induced Senescence through p53- and pRB-mediated Pathways, Journal of Biological Chemistry, vol.281, issue.47, pp.36221-36227, 2006. ,
DOI : 10.1074/jbc.M608236200
Mdm2 Plays a Positive Role as an Effector of p53-Dependent Responses, Cell Cycle, vol.6, issue.17, pp.2143-2147, 2007. ,
DOI : 10.4161/cc.6.17.4647
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas, Nature Reviews Cancer, vol.55, issue.12, pp.909-923, 2006. ,
DOI : 10.1002/gcc.20310
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer, Cancer Research, vol.61, issue.6, pp.2505-2512, 2001. ,
P53 in Breast Carcinomas: Association Between Presence of Mutation and Immunohistochemical Expression Using a Semiquantitative Approach, Pathology - Research and Practice, vol.194, issue.12, pp.815-819, 1998. ,
DOI : 10.1016/S0344-0338(98)80083-6
A simple p53 functional assay for screening cell lines, blood, and tumors., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3963-3967, 1995. ,
DOI : 10.1073/pnas.92.9.3963
<i>TP53</i> Status and Response to Chemotherapy in Breast Cancer, Pathobiology, vol.75, issue.2, pp.132-139, 2008. ,
DOI : 10.1159/000123851
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy, British Journal of Cancer, vol.18, issue.8, pp.1157-1164, 2007. ,
DOI : 10.1038/sj.onc.1200812
High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors, Cancer Research, vol.69, issue.2, pp.663-671, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-1560
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm, Cancer Cell, vol.12, issue.4, pp.303-312, 2007. ,
DOI : 10.1016/j.ccr.2007.10.001
Surfing the p53 network, Nature, vol.408, issue.6810, pp.307-310, 2000. ,
DOI : 10.1038/35042675
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes, Oncogene, vol.47, issue.15, pp.2157-2165, 2007. ,
DOI : 10.1158/1078-0432.CCR-05-0507
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nature Cell Biology, vol.113, issue.5, pp.573-580, 2007. ,
DOI : 10.1074/jbc.M306938200
A common gain of function of p53 cancer mutants in inducing genetic instability, Oncogene, vol.60, issue.7, pp.949-956, 2010. ,
DOI : 10.1038/nri1804
Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection, Clinical Cancer Research, vol.12, issue.1, pp.62-69, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-0413
URL : https://hal.archives-ouvertes.fr/hal-00018575
MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancera, Human Mutation, vol.358, issue.9, pp.1020-1025, 2010. ,
DOI : 10.1002/humu.21313
Mutation and Expression of TP53 in Malignant Melanomas, Recent Results in Cancer Research, vol.139, pp.137-154, 1995. ,
DOI : 10.1007/978-3-642-78771-3_10
Types and localisation of p53 gene mutations, Lung Cancer, vol.34, issue.2, pp.47-51, 2001. ,
DOI : 10.1016/S0169-5002(01)00344-0
Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation, Journal of Zhejiang University SCIENCE B, vol.8, issue.2, pp.81-87, 2007. ,
DOI : 10.1631/jzus.2007.B0081
The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1157-1167, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1029
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, issue.11, pp.1973-1976, 2010. ,
DOI : 10.3324/haematol.2010.023697
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma, International Journal of Oncology, vol.36, issue.3, pp.699-706, 2010. ,
Molecular Classification of Breast Cancer: Limitations and Potential, The Oncologist, vol.11, issue.8, pp.868-877, 2006. ,
DOI : 10.1634/theoncologist.11-8-868
Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000. ,
DOI : 10.1038/35021093
Triple-negative breast cancer--current status and future directions, Annals of Oncology, vol.20, issue.12, pp.1913-1927, 2009. ,
DOI : 10.1093/annonc/mdp492
URL : http://annonc.oxfordjournals.org/cgi/content/short/20/12/1913
Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers, Annals of Oncology, vol.18, issue.7, pp.1285-1286, 2007. ,
DOI : 10.1093/annonc/mdm360
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study, JAMA, vol.295, issue.21, pp.2492-2502, 2006. ,
DOI : 10.1001/jama.295.21.2492
p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer, Japanese Journal of Clinical Oncology, vol.39, issue.4, pp.217-224, 2009. ,
DOI : 10.1093/jjco/hyp007
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype, Clinical Cancer Research, vol.14, issue.5, pp.1368-1376, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1658
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001. ,
DOI : 10.1073/pnas.191367098
PROGNOSTIC SIGNIFICANCE OF THE CO-EXPRESSION OF p53 AND c-erbB-2 PROTEINS IN BREAST CANCER, The Journal of Pathology, vol.47, issue.1, pp.31-38, 1996. ,
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer, Journal of Clinical Oncology, vol.20, issue.17, pp.3628-3636, 2002. ,
DOI : 10.1200/JCO.2002.02.026
Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis, British Journal of Cancer, vol.5, issue.8, pp.1165-1174, 2007. ,
DOI : 10.1016/j.biocel.2004.09.006
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer, Oncogene, vol.21, issue.49, pp.7593-7597, 2002. ,
DOI : 10.1038/sj.onc.1205932
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer, Breast Cancer, vol.2, issue.2, pp.172-178, 2006. ,
DOI : 10.2325/jbcs.13.172
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support, International Journal of Cancer, vol.24, issue.3, pp.290-296, 2002. ,
DOI : 10.1002/ijc.10478
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Annals of Oncology, vol.17, issue.10, pp.1504-1511, 2006. ,
DOI : 10.1093/annonc/mdl147
p53 alterations in human cancer: more questions than answers, Oncogene, vol.10, issue.15, pp.2145-2156, 2007. ,
DOI : 10.1006/jmbi.1999.3174
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy, The Lancet, vol.360, issue.9336, pp.852-854, 2002. ,
DOI : 10.1016/S0140-6736(02)09969-5
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin???Cyclophosphamide Regimen, PLoS Medicine, vol.21, issue.3, p.90, 2007. ,
DOI : 10.1371/journal.pmed.0040090.st009
URL : https://hal.archives-ouvertes.fr/inserm-00700961
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers, The Oncologist, vol.15, issue.3, pp.246-252, 2010. ,
DOI : 10.1634/theoncologist.2009-0243
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors, International Journal of Cancer, vol.104, issue.4, pp.991-997, 2009. ,
DOI : 10.1002/ijc.24049
URL : https://hal.archives-ouvertes.fr/inserm-00498765
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nature Medicine, vol.19, issue.7, pp.811-814, 1996. ,
DOI : 10.1016/0959-8049(94)00213-O
TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains, Genes, Chromosomes and Cancer, vol.53, issue.1, pp.71-75, 1995. ,
DOI : 10.1002/gcc.2870140113
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis, Cancer Cell, vol.3, issue.4, pp.387-402, 2003. ,
DOI : 10.1016/S1535-6108(03)00079-5
p73 and p63 protein stability: the way to regulate function?, Biochemical Pharmacology, vol.66, issue.8, pp.1555-1561, 2003. ,
DOI : 10.1016/S0006-2952(03)00511-2
When p53 needs p73 to be functional ??? forced p73 expression induces nuclear accumulation of endogenous p53 protein, Cancer Letters, vol.197, issue.1-2, pp.99-103, 2003. ,
DOI : 10.1016/S0304-3835(03)00089-2
p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer, Clinical Cancer Research, vol.11, issue.20, pp.7328-7333, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0507
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes, Annals of Oncology, vol.19, issue.7, pp.1261-1265, 2008. ,
DOI : 10.1093/annonc/mdn039
mutations as prognostic variables in tumours from breast cancer patients, Acta Oncologica, vol.88, issue.4, pp.600-607, 2008. ,
DOI : 10.1056/NEJM199710023371401
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status, Journal of Cancer Research and Clinical Oncology, vol.3, issue.7, pp.420-428, 2005. ,
DOI : 10.1007/s00432-005-0670-3
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines, International Journal of Cancer, vol.9, issue.Suppl 1, pp.1813-1821, 2010. ,
DOI : 10.1002/ijc.25512
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, Cancer Research, vol.60, issue.8, pp.2155-2162, 2000. ,
Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy, Breast Cancer Research and Treatment, vol.126, issue.3, pp.777-788, 2010. ,
DOI : 10.1007/s10549-009-0560-5
The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2, Annals of Oncology, vol.11, issue.6, pp.647-663, 2000. ,
DOI : 10.1023/A:1008390429428
p53 status and the efficacy of cancer therapy in vivo, Science, vol.266, issue.5186, pp.807-810, 1994. ,
DOI : 10.1126/science.7973635